Results 81 to 90 of about 3,531,639 (330)

Interleukin‐6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal Analyses

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral muscular dystrophy type 1 (FSHD1) is a progressive neuromuscular disorder with no approved treatments. Identifying reliable biomarkers is critical to monitor disease severity, activity, and progression. Interleukin‐6 (IL‐6) has been proposed as a candidate biomarker, but longitudinal validation is limited ...
Jonathan Pini, Emanuela Martinuzzi, Sandra Dhifallah, Abderhmane Slioui, Angela Puma, Luisa Villa, Michele Cavalli, Andra Ezaru, Jérémy Garcia, Manuela Gambella, Federico Torre, Luca Jacopo Pavan, Nicolas Glaichenhaus, Sabrina Sacconi   +13 more
wiley   +1 more source

Inhaled Interleukin-10 before and after induction of experimental endotoxemia in the rat : effects on the inflammatory response [PDF]

, 2007
To determine the effects of inhaled IL-10 at different doses and different time points on the pulmonary and systemic inflammatory response during endotoxemia, 48 ventilated, anaesthetized rats (mean body weight ± standard deviation, 500 ± 33g) were ...
Nguyen, Ngoc-Thach
core  

Frailty Exacerbates Disability in Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration‐matched control PMS group (n = 53).
Taylor R. Wicks, Anna Wolska, Diala Ghazal, Dejan Jakimovski, Bianca Weinstock‐Guttman, Alexander Burnham, Niels Bergsland, Michael G. Dwyer, Alan T. Remaley, Robert Zivadinov, Murali Ramanathan   +10 more
wiley   +1 more source

FK 506 pre-treatment is associated with reduced levels of tumor necrosis factor and interleukin 6 following hepatic ischemia/reperfusion [PDF]

, 1993
Using a rat model, the effect of pre-treatment with FK 506 on hepatic ischemia/reperfusion injury was investigated. All control animals died within 72 h of the ischemia/reperfusion injury.
Aarden, Billiau, Camussi, Chollet-Martin, Colletti, Colletti, Craig J. McClain, David H. Van Thiel, Farber, Ferrante, Fischer, Francavilla, Francavilla, Gamble, Gauldie, Giorgio M. Zetti, Hajjar, Harding, Hayashi, Hishinuma, Honchel, Howard, Jirik, Judith S. Gavaler, Kahan, Kahn, Kawakani, Kim, Kim, Kino, Kishimoto, Kishimoto, Kramer, Lotz, Magilavy, Mahmoud F. Sakr, Makowka, Makowka, Matuschak, Maury, Mazzaferro, Meer, Miyahara, Mizel, Nagakawa, Nagakawa, Nawroth, Nordan, Nordan, Pennica, Perez-Tamayo, Pohlman, Sakai, Sakr, Shalaby, Shaw, Siekierka, Starzl, Starzl, Strieter, Takahashi, Thomas E. Starzl, Van Snick, Wankowicz, Yushimira   +64 more
core   +1 more source

Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin, Hui‐An Lin, Sheng‐Feng Lin   +2 more
wiley   +1 more source

Interleukin-6 gene (IL-6): a possible role in brain morphology in the healthy adult brain [PDF]

, 2012
Background: Cytokines such as interleukin 6 (IL-6) have been implicated in dual functions in neuropsychiatric disorders. Little is known about the genetic predisposition to neurodegenerative and neuroproliferative properties of cytokine genes.
A Kitamura, AA Willette, AH Miller, AL Jefferson, AL Marsland, AL Sousa, American Psychiatric Association, Astrid V Rauch, AT Beck, B Balasubramaniam, B Viviani, Bernhard T Baune, BL Pierce, BT Baune, BT Baune, Carsten Konrad, CF Terry, Christina Uhlmann, CS Carlson, Dominik Grotegerd, E Brietzke, E Halperin, E Vermetten, Eva Birosova, F Faul, GM MacQueen, H Tilg, H-U Wittchen, Harald Kugel, I HapMap, I Hickie, I Morales, J Ashburner, J Hannestad, J McAfoose, J Oh, JA Wagner, JE Malberg, JM Gatt, JM Kim, Jochen Bauer, JP Godbout, K Kasai, K Pham, Katharina Domschke, KK Bowen, L Capuron, L Christiansen, L Vallieres, L Vitkovic, LD Ward, M Bonafe, M Murphy, M Pickering, M Yamada, MA Kahn, MA Munoz-Fernandez, MK Kang, ML Monje, MT Heneka, N Ohbayashi, N Pervaiz, N Raz, N Tzourio-Mazoyer, O Davidovich, O Islam, P Angelopoulos, P Oeth, P Videbech, Patricia Ohrmann, RA Gadient, RA Gadient, RM Thomas, S Campbell, S Eickhoff, S Ihara, S Ihara, S Lehrl, S Matsuda, S Toulmond, SA Loddick, SD Forman, Sonja Schöning, T Beblo, T Frodl, T Hama, T Hama, T Hirano, Thomas Suslow, U Dannlowski, Udo Dannlowski, V Tancredi, Volker Arolt, Walter Heindel, Y Akaneya, Y Dowlati, Y Kushima, Y Kushima, YP Peng, YY Wu   +99 more
core   +3 more sources

Interleukin-21 Receptor Gene Polymorphisms in Kawasaki Disease [PDF]

Korean Circulation Journal, 2013
Interleukin-21 receptor (IL-21R) gene polymorphism is related with the development of systemic vasculitis. In this study, we investigated the polymorphisms of IL-21R gene in patients with Kawasaki disease (KD).We genotyped the promoter region of IL-21R gene (-2500 bp to +1 bp) in 100 patients with KD and 100 healthy controls.
Kim, Mi Hyun, Bae, Yon Jung, Lee, Hyun Keun, Lee, Yeong Ro, Lee, Dong Hoon, Bae, Kiho, Koh, Sang Baek, Namgoong, Mee Kyung, Cha, Byung Ho, Lee, Hae Yong   +9 more
openaire   +2 more sources

Fluid and Neuroimaging Biomarkers in Microgliopathy Colony‐Stimulating Factor‐1 Receptor‐Related Disorders

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela, Madison Reeves, Karen Jansen‐West, Judith Dunmore, Yuping Song, Audrey Strongosky, Sunil Gandhi, Gilana Pikover, Matt Blurton‐Jones, Robert C. Spitale, Erik H. Middlebrooks, Leonard Petrucelli, Mercedes Prudencio, Zbigniew K. Wszolek   +13 more
wiley   +1 more source

Clinical Trials of Immunogene Therapy for Spontaneous Tumors in Companion Animals [PDF]

, 2014
Despite the important progress obtained in the treatment of some pets’ malignancies, new treatments need to be developed. Being critical in cancer control and progression, the immune system’s appropriate modulation may provide effective therapeutic ...
Finocchiaro, Liliana Maria Elena, Glikin, Gerardo Claudio   +1 more
core   +4 more sources

Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti‐AChR Antibody‐Positive Myasthenia Gravis: FGF‐19 as a Novel Biomarker

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo, Deyou Peng, Zhouao Zhang, Mingjin Yang, Xinyan Guo, Tianyu Ma, Xiaoyu Huang, Mingming Xu, Linlin Fu, Yong Zhang   +9 more
wiley   +1 more source